1. Home
  2. REE vs LIXT Comparison

REE vs LIXT Comparison

Compare REE & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REE Automotive Ltd.

REE

REE Automotive Ltd.

HOLD

Current Price

$0.75

Market Cap

21.7M

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$4.09

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REE
LIXT
Founded
2011
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7M
25.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REE
LIXT
Price
$0.75
$4.09
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$11.75
N/A
AVG Volume (30 Days)
109.4K
106.1K
Earning Date
12-17-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$183,000.00
N/A
Revenue This Year
$327.73
N/A
Revenue Next Year
$36,888.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.64
52 Week High
$10.24
$6.26

Technical Indicators

Market Signals
Indicator
REE
LIXT
Relative Strength Index (RSI) 49.49 46.19
Support Level $0.65 $3.50
Resistance Level $0.82 $4.34
Average True Range (ATR) 0.07 0.31
MACD 0.01 0.01
Stochastic Oscillator 62.99 57.89

Price Performance

Historical Comparison
REE
LIXT

About REE REE Automotive Ltd.

REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: